Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
CN

NASDAQ · CNTB

Connect Biopharma Holdings Limited

Healthcare · Biotechnology

$0.91

Up+$0.01 (+0.84%)

Updated Oct 7, 2026, 7:33 AM

SID Score

2.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
136.39M
P/E ratio
-3.75
Dividend yield
0.00%
52-week range
$0.89 – $3.82
Volume
1.84M
Avg. volume
268.18K

Price performance · CNTB

CNTB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

CNTB closed at $0.91 after 21 trading sessions, down 52.60% for the selected period.

Last close
$0.91
Period change
-52.60%
Period low
$0.90
Period high
$2.06
Daily close
View OHLC price history
CNTB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$0.886$0.98$0.8501$0.90541.84M
Oct 5, 2026$0.927$0.97$0.89$0.89791.43M
Oct 2, 2026$0.98$1.08$0.886$0.9274.2M
Oct 1, 2026$1.115$1.12$0.9433$0.97977.94M
Sep 30, 2026$1.89$1.89$1.07$1.10165.63M
Sep 29, 2026$1.06$1.09$0.98$0.9921.6M
Sep 28, 2026$1.08$1.11$1.05$1.082.46M
Sep 25, 2026$1.09$1.12$1.06$1.08804.33K
Sep 24, 2026$1.07$1.11$1.065$1.10778.22K
Sep 23, 2026$1.21$1.23$1.065$1.071.41M
Sep 22, 2026$1.28$1.28$1.205$1.2151.22M
Sep 21, 2026$1.27$1.33$1.20$1.321.36M
Sep 18, 2026$1.25$1.32$1.25$1.281.28M
Sep 17, 2026$1.22$1.295$1.1101$1.291.81M
Sep 16, 2026$1.14$1.38$1.13$1.243.43M
Sep 15, 2026$1.27$1.30$1.061$1.1711.69M
Sep 14, 2026$1.79$1.82$1.58$1.7252.69M
Sep 11, 2026$2.07$2.0991$1.94$2.04878.04K
Sep 10, 2026$1.99$2.075$1.91$2.06768.57K
Sep 9, 2026$1.91$2.10$1.89$2.01963.89K
Sep 8, 2026$1.92$1.97$1.80$1.911.19M

Latest CNTB news

The latest Smart Investors Daily articles mentioning CNTB.

Stock researchCompany · Overview

CNTB research

Overview

Company profile and research snapshot.

Company profile

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$9.00
Implied upside
—
Analysts
—
CNTB recent ratings
DateFirmRatingTarget
Oct 2, 2026HC Wainwright & Co.Buy—
Sep 30, 2026BTIGBuy—
Sep 22, 2026OppenheimerOutperform—
Sep 17, 2026HC Wainwright & Co.Buy—
Sep 16, 2026Canaccord GenuityBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program

Rademikibart significantly reduced treatment failure and new moderate-to-severe COPD exacerbations in the Seabreeze STAT study, while Connect Biopharma said it plans to discuss a Phase 3 registrational program with the FDA. Key Investor TakeawaysConnect Biopharma (NASDAQ:CNTB) reported positive preliminary topline data from the 159-patient Phase 2 Seabreeze STAT COPD trial of rademikibart.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By